Evidence map›Paper›PMID 30323810›Full record

ArticleFrontiers in immunology2018

Corrigendum: Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance.

Sarah A Greaves, Jacob N Peterson, Raul M Torres, Roberta Pelanda

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Sarah A GreavesDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Jacob N PetersonDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Raul M TorresDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.
Roberta PelandaDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States.

Funding

Tolerance in Polyclonal and Oligoclonal Immune SystemsR01AI052310 · NIAID · UNIVERSITY OF COLORADO DENVER · PI PELANDA, ROBERTA · 2003 to 2017
$5.0M
Testing an alternative model of central B cell toleranceR21AI131639 · NIAID · UNIVERSITY OF COLORADO DENVER · PI PELANDA, ROBERTA · 2017 to 2018
$428k
NIAID NIH HHS R01 AI052310NIAID NIH HHS R21 AI131639
6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2018.00707.].

Indexed as

autoreactive B cellsB cell developmentB cellsB cell toleranceBCR signalingERKMAP kinasemouse models

Identifiers

PMID30323810
PMCPMC6174676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.